The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing ...
Abstracts represent exciting research progress across four cancers where patients have limited treatment options "While a robust Phase 3 clinical trial program in gastric/gastroesophageal junction ...
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results